• DNDi logo
  • Our work
    • Diseases
      • Sleeping sickness
      • Visceral leishmaniasis
      • Cutaneous leishmaniasis
      • Chagas disease
      • Filaria: river blindness
      • Mycetoma
      • Paediatric HIV
      • Cryptococcal meningitis
      • Hepatitis C
      • Dengue
      • COVID-19
      • Antimicrobial resistance
    • Research & development
      • R&D portfolio & list of projects
      • Drug discovery
      • Translational research
      • Clinical trials
      • Registration & access
      • Treatments delivered
    • Advocacy
      • Open and collaborative R&D
      • Transparency of R&D costs
      • Pro-access policies
  • Networks & partners
    • Partnerships
      • Our partners
      • Partnering with us
    • Global networks
      • Chagas Platform
      • HAT Platform
      • HELP Helminth Elimination Platform
      • LEAP Platform
      • redeLEISH Network
    • DNDi worldwide
      • DNDi Global Headquarters
      • DNDi DRC
      • DNDi East Africa
      • DNDi Japan
      • DNDi Latin America
      • DNDi North America
      • DNDi South Asia
      • DNDi South-East Asia
      • DNDi Southern Africa
  • News & resources
    • News & stories
      • News
      • Stories
      • Statements
      • Viewpoints
      • Social media
      • eNews Newsletter
    • Press
      • Press releases
      • In the media
    • Resources
      • Scientific articles
      • Our publications
      • Videos
    • Events
  • About us
    • About
      • Who we are
      • How we work
      • Our strategy
      • Our donors
      • Annual reports
    • Our people
      • Our leadership
      • Our governance
      • Contact us
    • Work with us
      • Working at DNDi
      • Job opportunities
      • Requests for proposal
  • Donate
DNDi logo
  • DNDi logo
  • Our work
    • Diseases
      • Sleeping sickness
      • Visceral leishmaniasis
      • Cutaneous leishmaniasis
      • Chagas disease
      • Filaria: river blindness
      • Mycetoma
      • Paediatric HIV
      • Cryptococcal meningitis
      • Hepatitis C
      • Dengue
      • COVID-19
      • Antimicrobial resistance
    • Research & development
      • R&D portfolio & list of projects
      • Drug discovery
      • Translational research
      • Clinical trials
      • Registration & access
      • Treatments delivered
    • Advocacy
      • Open and collaborative R&D
      • Transparency of R&D costs
      • Pro-access policies
  • Networks & partners
    • Partnerships
      • Our partners
      • Partnering with us
    • Global networks
      • Chagas Platform
      • HAT Platform
      • HELP Helminth Elimination Platform
      • LEAP Platform
      • redeLEISH Network
    • DNDi worldwide
      • DNDi Global Headquarters
      • DNDi DRC
      • DNDi East Africa
      • DNDi Japan
      • DNDi Latin America
      • DNDi North America
      • DNDi South Asia
      • DNDi South-East Asia
      • DNDi Southern Africa
  • News & resources
    • News & stories
      • News
      • Stories
      • Statements
      • Viewpoints
      • Social media
      • eNews Newsletter
    • Press
      • Press releases
      • In the media
    • Resources
      • Scientific articles
      • Our publications
      • Videos
    • Events
  • About us
    • About
      • Who we are
      • How we work
      • Our strategy
      • Our donors
      • Annual reports
    • Our people
      • Our leadership
      • Our governance
      • Contact us
    • Work with us
      • Working at DNDi
      • Job opportunities
      • Requests for proposal
  • Donate
Home > News

DNDi 2021 Projects of the Year recognize partners and colleagues for their work in developing new treatments for visceral leishmaniasis and sleeping sickness

6 Oct 2021
Share on twitter
Share on facebook
Share on linkedin
Share on email
Share on print
  • English
    • English
    • Français
    • 日本語

The Drugs for Neglected Diseases initiative (DNDi) is very pleased to announce two 2021 Projects of the Year, which recognize DNDi R&D teams and key partners for outstanding progress in the areas of drug discovery and clinical research. Nominated by the DNDi Scientific Advisory Committee and selected by the DNDi Executive Board, the 2021 awards recognize two projects from among the more than 50 active projects in DNDi’s R&D portfolio.

S07 series lead optimization for visceral leishmaniasis – 2021 Project of the Year in drug discovery

Existing treatments for visceral leishmaniasis can be painful, toxic, lengthy, costly, and poorly adapted for use in the most affected communities. To provide people of all ages with safer, simpler, and more effective treatment options, DNDi and partners are discovering entirely new compounds that can be developed into all-oral drugs.

The S07 series is the first project to emerge into lead optimization from the NTD Drug Discovery Booster, a global consortium of pharmaceutical companies that have opened their libraries of millions of unique molecules so that researchers can screen them in silico and in vitro to identify new potential treatments for neglected tropical diseases. With support from the Japanese Global Health Innovative Technology (GHIT) Fund, among other donors, more than 18,000 compounds have been screened for antiparasitic activity to date through this international initiative.

Following Discovery Booster efforts conducted in partnership with Takeda Pharmaceutical Company Limited to identify and advance novel compounds against visceral leishmaniasis, the DNDi-Takeda collaboration is now progressing medicinal chemistry optimization for S07 series lead compounds to further enhance their safety and efficacy profiles. With support from the GHIT Fund, the partnership aims to advance an optimized lead to deliver a pre-clinical candidate compound by 2023.

‘The S07 series is a prime example of the advances our discovery partnerships are making to find the missing tools we need to meet patient’s needs and reach global targets for neglected tropical diseases,’ said Dr Laurent Fraisse, Research and Development Director at DNDi. ‘We congratulate Takeda and the DNDi Drug Discovery team for their progress, which demonstrates that innovative collaborations like the NTD Drug Discovery Booster can play a powerful role in accelerating scientific discovery and future medical innovation.’

Acoziborole for sleeping sickness – 2021 Project of the Year in clinical research

DNDi’s goal is to revolutionize the treatment of sleeping sickness – or human African trypanosomiasis (HAT) – by replacing toxic, cumbersome medicines with simple, all-oral cures that can help eliminate the disease altogether. In 2018, DNDi and partners completed the development of the first all-oral treatment for sleeping sickness, fexinidazole.

Together with Sanofi, our industrial partner for fexinidazole, we are now working to complete the development of acoziborole, a single-dose oral treatment for sleeping sickness that can be administered at the point of diagnosis.

‘Acoziborole can provide a dramatic boost for sleeping sickness ‘test-and-treat’ programmes – particularly in remote communities and settings affected by conflict and instability – and help anchor efforts to sustain elimination of the disease,’ said Dr Fraisse. ‘These advances in clinical development would not be possible without the steady commitment of Sanofi, the Institut National de Recherche Biomédicale (INRB) of the Democratic Republic of Congo (DRC), the National HAT Control Programmes of the DRC and Guinea, and the DNDi sleeping sickness team.’

In 2012, acoziborole became the first new chemical entity to enter clinical development from DNDi’s own lead optimization programme. Last year, our teams completed 18-month post treatment follow-up for all patients in DNDi’s pivotal Phase II/III clinical trial for the drug in the Democratic Republic of Congo (DRC) and Guinea. Following its approval, Sanofi will be responsible for the manufacturing, supply, registration, and distribution of acoziborole. The treatment will be provided to patients free of charge through affected countries’ public health systems thanks to a 20-year collaboration between Sanofi and the World Health Organization.

Read more about visceral leishmaniasis

Read more about sleeping sickness

Clinical trials Drug discovery Sleeping sickness Visceral leishmaniasis

Read, watch, share

Loading...
Laboratory activities
Press releases
18 May 2022

Consortium formed to discover antivirals for COVID-19 receives NIH funding to develop globally accessible treatments for pandemics

Researcher working in a laboratory setting
News
18 May 2022

Health Journalists from Africa receive grants to report on COVID-19

After a serious outbreak of dengue fever in the Chinatown area of Bangkok in which a man died, the Bangkok Metropolitan Administration came in to fumigate the area and advise locals on possible breeding ground of mosquitos.
Press releases
29 Apr 2022

Ministry of Health, Malaysia and Drugs for Neglected Diseases initiative combine forces to lead the battle against dengue

News
22 Apr 2022

DNDi calls for nominations for a new Audit Committee Member

Microscope and computer
Press releases
20 Apr 2022

DNDi and BenevolentAI collaborate to accelerate life-saving drug discovery research in dengue

Woman looking up
Stories
13 Apr 2022

Early diagnosis and treatment can save millions of lives

Statements
12 Apr 2022

DNDi intervention at the Intergovernmental Negotiating Body first round of public hearings

Dr Monique Wasunna, Eastern Africa Regional Director, DNDi; Carole Lanteri, Ambassador and Permanent Representative at UNOG for the Government of the Principality of Monaco; Dr Bernard Pécoul, Executive Director, DNDi
Press releases
8 Apr 2022

Government of the Principality of Monaco supports DNDi to increase access to improved treatment for children with HIV

VIEW ALL

Help neglected patients

To date, we have delivered nine new treatments, saving millions of lives.

Our goal is to deliver 25 new treatments in our first 25 years. You can help us get there. 

GIVE NOW
DNDi logo
Facebook-f
Twitter
Instagram
Linkedin-in
Youtube
International non-profit developing safe, effective, and affordable treatments for the most neglected patients.

Learn more

  • Diseases
  • R&D portfolio
  • Policy advocacy

Get in touch

  • Our offices
  • Contact us
  • Integrity Line

Support us

  • Donate
  • Subscribe to eNews

Work with us

  • Join research networks
  • Jobs
  • RFPs
  • Terms of Use   
  •   Acceptable Use Policy   
  •   Privacy Policy   
  •   Cookie Policy   
  •   Our policies   

  • Except for images, films and trademarks which are subject to DNDi’s Terms of Use, content on this site is licensed under a Creative Commons Attribution-NonCommercial-Share Alike 3.0 Switzerland License